2011
Phosphoproteomic Screen Identifies Potential Therapeutic Targets in Melanoma
Tworkoski K, Singhal G, Szpakowski S, Zito CI, Bacchiocchi A, Muthusamy V, Bosenberg M, Krauthammer M, Halaban R, Stern DF. Phosphoproteomic Screen Identifies Potential Therapeutic Targets in Melanoma. Molecular Cancer Research 2011, 9: 801-812. PMID: 21521745, PMCID: PMC3117976, DOI: 10.1158/1541-7786.mcr-10-0512.Peer-Reviewed Original ResearchMeSH KeywordsApoptosisCell Line, TumorCell MovementCell ProliferationErbB ReceptorsGene Expression Regulation, NeoplasticGene Knockdown TechniquesHEK293 CellsHumansInfant, NewbornMelanocytesMelanomaPhosphoproteinsPhosphorylationProteomicsReceptor Protein-Tyrosine KinasesReceptor, IGF Type 2RNA, Small InterferingSignal TransductionSkin NeoplasmsSTAT3 Transcription FactorConceptsTherapeutic targetReceptor tyrosine kinasesMelanoma cellsPotential therapeutic targetIdentifies potential therapeutic targetsActive receptor tyrosine kinasesTyrosine kinaseMelanoma cell migrationReceptor expressionBreast cancerAxl knockdownAutocrine circuitTherapeutic interventionsCancer subtypesReceptor tyrosine kinase activationTyrosine kinase activationNovel targetActivated receptorsAxlRNA knockdownMelanomaCell migrationHER3KnockdownIGF1R
2010
PLX4032, a selective BRAFV600E kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAFWT melanoma cells
Halaban R, Zhang W, Bacchiocchi A, Cheng E, Parisi F, Ariyan S, Krauthammer M, McCusker JP, Kluger Y, Sznol M. PLX4032, a selective BRAFV600E kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAFWT melanoma cells. Pigment Cell & Melanoma Research 2010, 23: 190-200. PMID: 20149136, PMCID: PMC2848976, DOI: 10.1111/j.1755-148x.2010.00685.x.Peer-Reviewed Original ResearchConceptsMelanoma cellsTumor cellsMelanoma tumor cellsPrimary melanoma cellsMetastatic tumor cellsStatus of mutationsClinical responseRate of proliferationAdvanced lesionsInhibitor PLX4032Kinase inhibitorsPLX4032ERK pathwayCell migrationNRASDownstream effectorsCell adherenceERK1/2CellsProliferationCell cycle controlMobility of cellsActive ERK1/2Therapy
1993
met and HGF-SF in normal melanocytes and melanoma cells.
Halaban R, Rubin J, White W. met and HGF-SF in normal melanocytes and melanoma cells. 1993, 65: 329-39. PMID: 8380740.Peer-Reviewed Original ResearchConceptsHGF-SFFactor-dependent cellsMelanoma cellsNormal human melanocytesSignal transductionMouse melanocytesTumorigenic phenotypeHuman melanocytesHuman melanoma cellsNormal melanocytesAutocrine loopMelanocytesHuman melanomaMalignant conversionMelanin contentTyrosinase activityEctopic sitesCellsSynergistic factorExpressionBFGFERK2TransductionPhosphorylationProtein
1992
Scatter factor and hepatocyte growth factor: activities, properties, and mechanism.
Bhargava M, Joseph A, Knesel J, Halaban R, Li Y, Pang S, Goldberg I, Setter E, Donovan M, Zarnegar R. Scatter factor and hepatocyte growth factor: activities, properties, and mechanism. Molecular Cancer Research 1992, 3: 11-20. PMID: 1534687.Peer-Reviewed Original ResearchConceptsHepatocyte growth factorScatter factorPartial amino acid sequence dataAmino acid sequence dataAmino acid sequenceFibroblast-derived proteinHuman smooth muscle cellsVascular endothelial cell typesEndothelial cell typesGrowth factorSignificant homologyPosttranslational modificationsSequence dataRapid phosphorylationAcid sequenceBiological activityTyrosine residuesProtein productsCohesive coloniesCommon antigenic determinantsCell typesSpecies-related differencesProteinSerum-derived proteinsHuman hepatocyte growth factor